Literature DB >> 9851753

Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma.

E Arvat1, R Giordano, J Ramunni, G Arnaldi, A Colao, R Deghenghi, G Lombardi, F Mantero, F Camanni, E Ghigo.   

Abstract

We previously reported that in Cushing's disease (CD) the ACTH- and cortisol (F)-releasing activity of Hexarelin (HEX), a GH secretagogue, is exaggerated with respect to that in normal subjects and is higher than that of human CRH (hCRH), but it is absent in Cushing's syndrome. Our aim was to extend the study about the effects of HEX (2.0 microg/kg, iv) on ACTH and F secretion in 21 patients with CD (3 men and 18 women, 16-68 yr old). Based on magnetic resonance imaging, 15 CD patients had pituitary microadenoma, and 6 had macroadenoma. The results in CD patients were compared with those in 27 normal age-matched controls (NS; 10 men and 17 women, 24-69 yr old). Basal ACTH and F levels in CD were similar in patients with microadenom (mean+/-SEM, 78.3+/-7.2 pg/mL and 237.1+/-23.6 microg/L, respectively) and macroadenoma (57.4+/-9.0 pg/mL and 196.9+/-20.1 microg/L, respectively) and were higher (P < 0.001) than those in NS (17.7+/-2.0 pg/mL and 115.3+/-6.7 microg/L, respectively). In microadenoma CD patients, HEX induced marked ACTH and F increases (delta peak, mean+/-SEM: 261.2+/-77.6 pg/mL and 226.1+/-87.2 microg/L, respectively), which were higher (P < 0.04) than those induced by hCRH (45.6+/-16.9 pg/mL and 84.6+/-25.7 microg/L, respectively). Moreover, in microadenoma CD patients, the ACTH and F responses to HEX were higher (P < 0.001) than those in NS (18.5+/-4.0 pg/mL and 36.1+/-6.8 microg/L, respectively). In macroadenoma CD patients, HEX induced a slight, but significant increase (P < 0.02) in ACTH and F levels (33.9+/-18.0 pg/mL and 89.6+/-34.3 microg/L, respectively), which was not significantly different from that elicited by hCRH (20.0+/-7.0 pg/mL and 54.8+/-21.3 microg/L, respectively). In macroadenoma CD patients, the ACTH and F responses to HEX and hCRH were, in turn, similar to those in NS. In conclusion, our findings demonstrate that the ACTH and F hyperresponsiveness to HEX is present in Cushing's disease with micro-, but not macro- ACTH-secreting pituitary adenoma. This finding agrees with other evidence pointing toward differences in the hormonal behavior between micro- and ACTH-secreting pituitary macroadenomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851753     DOI: 10.1210/jcem.83.12.5355

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  GH secretagogues and hypothalamo-pituitary-adrenal axis.

Authors:  M Boscaro; T Mancini
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

2.  GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Authors:  J H A Oliveira; J G H Vieira; J Abucham; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

Review 3.  Dynamic testing in Cushing's syndrome.

Authors:  Blerina Kola; Ashley B Grossman
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 4.  Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome.

Authors:  Roberta Giordano; Andreea Picu; Fabio Broglio; Lorenza Bonelli; Matteo Baldi; Rita Berardelli; Ezio Ghigo; Emanuela Arvat
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

5.  In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing's syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression.

Authors:  M C Machado; S V Sá; T S Goldbaum; M Catania; V C Campos; M L Corrêa-Giannella; D Giannella-Neto; L R Salgado
Journal:  J Endocrinol Invest       Date:  2007-04       Impact factor: 4.256

Review 6.  Biologic activities of growth hormone secretagogues in humans.

Authors:  E Ghigo; E Arvat; R Giordano; F Broglio; L Gianotti; M Maccario; G Bisi; A Graziani; M Papotti; G Muccioli; R Deghenghi; F Camanni
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.